cisapride has been researched along with Esophagitis, Peptic in 57 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Esophagitis, Peptic: INFLAMMATION of the ESOPHAGUS that is caused by the reflux of GASTRIC JUICE with contents of the STOMACH and DUODENUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the safety and efficacy of cisapride in patients with gastroesophageal reflux disease." | 9.08 | Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. ( Long, JF; Richter, JE, 1995) |
| "The influence of Cisapride on food-stimulated gastro-oesophageal reflux mechanisms was studied in a double-blind cross-over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro-oesophageal reflux and 12 with additional macroscopic oesophagitis." | 9.06 | Influence of cisapride on food-stimulated gastro-oesophageal reflux: a radiological study. ( Aksglade, K; Funch-Jensen, P; Gelineck, J; Thommesen, P, 1990) |
| " The pharmacological activity of AFE and pure scopoletin at the same equivalent dose present in AFE was investigated in rat on gastro-esophageal inflammatory models (acid reflux esophagitis, acute gastritis induced by ethanol and serotonin, and chronic gastric ulcer induced by acetic acid); gastric biochemical parameters and gastrointestinal motility." | 7.77 | Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. ( Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W, 2011) |
| "Cisapride is a new drug which stimulates gastrointestinal motility via facilitation of acetylcholine release from myenteric nerves." | 7.76 | Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review. ( Richter, JE, 1989) |
| "Successful treatment of gastro-oesophageal reflux disease (GORD) has traditionally been assessed as healing of reflux oesophagitis, which may not be relevant in patients with moderate disease." | 6.68 | The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. ( Carling, L; Hatlebakk, JG; Johnsson, F; Thøgersen, T; Vilien, M; Wetterhus, S, 1997) |
| "Gastro-oesophageal reflux was very variable on both 24-h pH monitoring and acid reflux provocation test." | 6.67 | Cisapride in the treatment of gastro-oesophageal reflux disease. ( Atkinson, M; Evans, DF; Ledingham, SJ; Robertson, CS, 1993) |
| "Diagnosis of gastro-oesophageal reflux was made by measurement of intraluminal oesophageal pH combined with manometry." | 6.66 | Cisapride for gastro-oesophageal reflux and peptic oesophagitis. ( Auricchio, S; Boccieri, A; Capozzi, C; Cucchiara, S; Di Lorenzo, C; Staiano, A, 1987) |
| "Therefore, we diagnosed bronchial asthma associated with reflux esophagitis and gastroduodenal ulcer." | 5.29 | [A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1994) |
| "Cisapride is a new prokinetic agent that acts at gastric emptying, esophagic peristalsis and the pressure of the low esophagic sphincter." | 5.28 | [Results of the treatment of gastroesophageal reflux and peptic esophagitis using cisapride]. ( Carrasco Gandía, S; Lama Moré, R; Polanco Allue, I; Prieto Bozano, G, 1990) |
| "To evaluate the safety and efficacy of cisapride in patients with gastroesophageal reflux disease." | 5.08 | Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. ( Long, JF; Richter, JE, 1995) |
| "In patients with severe gastro-oesophageal reflux disease both cisapride and ranitidine demonstrably lower oesophageal acid exposure, but neither therapy predictably normalizes it." | 5.08 | A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis. ( Kahrilas, PJ; Pouderoux, P, 1995) |
| "The influence of Cisapride on food-stimulated gastro-oesophageal reflux mechanisms was studied in a double-blind cross-over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro-oesophageal reflux and 12 with additional macroscopic oesophagitis." | 5.06 | Influence of cisapride on food-stimulated gastro-oesophageal reflux: a radiological study. ( Aksglade, K; Funch-Jensen, P; Gelineck, J; Thommesen, P, 1990) |
| " The pharmacological activity of AFE and pure scopoletin at the same equivalent dose present in AFE was investigated in rat on gastro-esophageal inflammatory models (acid reflux esophagitis, acute gastritis induced by ethanol and serotonin, and chronic gastric ulcer induced by acetic acid); gastric biochemical parameters and gastrointestinal motility." | 3.77 | Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. ( Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W, 2011) |
| "Gastro-oesophageal reflux occurs when the pressure barrier of the lower oesophageal sphincter (LOS) fails due to a low basal pressure (less than or equal to 6 mm Hg), sphincteric relaxations or a noncompensated increase in intragastric pressure." | 3.76 | Pathophysiology and treatment of gastro-oesophageal reflux disease. ( Janssens, J; Vantrappen, G, 1989) |
| "Cisapride is a new drug which stimulates gastrointestinal motility via facilitation of acetylcholine release from myenteric nerves." | 3.76 | Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review. ( Richter, JE, 1989) |
| "Cisapride can increase the secretion function of salivary glands during the postprandial phase but not the fasting phase." | 2.69 | Salivary function in patients with reflux esophagitis: effect of cisapride. ( Chang, CS; Chen, GH; Chen, SD; Kao, CH, 1998) |
| "Omeprazole was significantly more effective than cisapride (P = 0." | 2.68 | A comparison of five maintenance therapies for reflux esophagitis. ( Badalamenti, S; Battaglia, G; Di Mario, F; Leandro, G; Mela, GS; Pantalena, M; Pilotto, A; Savarino, V; Termini, R; Vigneri, S, 1995) |
| "In an international, multicentre, double-blind trial, to document the therapeutic equivalence of two dosing regimens of cisapride on endoscopic healing and symptom improvement in patients with proven reflux oesophagitis grade I or II (Savary-Miller)." | 2.68 | Comparison of two dosing regimens of cisapride in the treatment of reflux oesophagitis. ( Bedogni, G; Bigard, MA; Hentschel, E; Hinojosa, J; Schütze, K; Van Waes, L, 1997) |
| "Successful treatment of gastro-oesophageal reflux disease (GORD) has traditionally been assessed as healing of reflux oesophagitis, which may not be relevant in patients with moderate disease." | 2.68 | The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. ( Carling, L; Hatlebakk, JG; Johnsson, F; Thøgersen, T; Vilien, M; Wetterhus, S, 1997) |
| "The cisapride induced increase in oesophageal contractile force and propagation velocity seems to enhance the clearance of gastro-oesophageal reflux." | 2.67 | Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study. ( Armstrong, D; Bettschen, HU; Blum, AL; Emde, C; Halter, F; Huber, T; Inauen, W; Merki, HS; Scheurer, U; Weber, B, 1993) |
| "We conducted a double-blind study comparing two dosage regimens of a prokinetic drug, cisapride (10 mg q." | 2.67 | Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. ( Geldof, H; Hazelhoff, B; Otten, MH, 1993) |
| "Gastro-oesophageal reflux was very variable on both 24-h pH monitoring and acid reflux provocation test." | 2.67 | Cisapride in the treatment of gastro-oesophageal reflux disease. ( Atkinson, M; Evans, DF; Ledingham, SJ; Robertson, CS, 1993) |
| "Cisapride was superior to placebo with regard to mucosal healing (p less than 0." | 2.67 | Healing of grade-II and III oesophagitis through motility stimulation with cisapride. ( Bollen, J; Laukens, P; Lepoutre, L; Van der Spek, P; Vanderlinden, I, 1990) |
| " One hundred and twenty-nine patients were assigned to one of four dosage schedules: cisapride 10 mg b." | 2.67 | Cisapride and cimetidine in the treatment of erosive esophagitis. ( Crowe, J; Dimitrov, B; Maleev, A; Mendizova, A; Mihova, A; Popov, P; Routhier, G; Silveira, J; Thomson, A; Vlahov, V, 1990) |
| "Diagnosis of gastro-oesophageal reflux was made by measurement of intraluminal oesophageal pH combined with manometry." | 2.66 | Cisapride for gastro-oesophageal reflux and peptic oesophagitis. ( Auricchio, S; Boccieri, A; Capozzi, C; Cucchiara, S; Di Lorenzo, C; Staiano, A, 1987) |
| "The vast majority of patients with GERD have mild symptoms, no gross endoscopic evidence of esophagitis, and little risk of developing complications." | 2.39 | Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. ( Reynolds, JC, 1996) |
| "Gastro-oesophageal reflux is a common phenomenon in infants, and is an aspecific complaint." | 2.38 | The diagnosis and treatment of gastro-oesophageal reflux disease in infants and children. ( Vandenplas, Y, 1993) |
| " Post-evening meal (PEM) dosing of H2-receptor antagonists appears to be a rational method of suppressing late evening gastric acidity, but on balance the symptomatic response of twice daily dosing is superior to once daily dosing." | 2.38 | Reflux esophagitis. ( Nio, CY; Schotborgh, RH; Tytgat, GN, 1990) |
| " Dinnertime dosing of cimetidine appears to be a rational method of suppressing late-evening gastric acidity." | 2.38 | Drug therapy of reflux oesophagitis: an update. ( Tytgat, GN, 1989) |
| "Therefore, we diagnosed bronchial asthma associated with reflux esophagitis and gastroduodenal ulcer." | 1.29 | [A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1994) |
| "A 46-year-old man with achalasia-like syndrome developed CREST syndrome 4 years later." | 1.29 | Achalasia-like syndrome as the first manifestation in a patient with CREST syndrome. ( Berenguer, J; Gálvez, C; Garrigues, V; Ponce, J; Valverde, J, 1996) |
| "Cisapride is a new prokinetic agent that acts at gastric emptying, esophagic peristalsis and the pressure of the low esophagic sphincter." | 1.28 | [Results of the treatment of gastroesophageal reflux and peptic esophagitis using cisapride]. ( Carrasco Gandía, S; Lama Moré, R; Polanco Allue, I; Prieto Bozano, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (21.05) | 18.7374 |
| 1990's | 43 (75.44) | 18.2507 |
| 2000's | 1 (1.75) | 29.6817 |
| 2010's | 1 (1.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahattanadul, S | 1 |
| Ridtitid, W | 1 |
| Nima, S | 1 |
| Phdoongsombut, N | 1 |
| Ratanasuwon, P | 1 |
| Kasiwong, S | 1 |
| Chapman, MJ | 1 |
| Nguyen, NQ | 1 |
| Fraser, RJ | 1 |
| Vigneri, S | 1 |
| Termini, R | 1 |
| Leandro, G | 1 |
| Badalamenti, S | 1 |
| Pantalena, M | 1 |
| Savarino, V | 1 |
| Di Mario, F | 1 |
| Battaglia, G | 1 |
| Mela, GS | 1 |
| Pilotto, A | 1 |
| Tytgat, GN | 5 |
| Blum, AL | 3 |
| Verlinden, M | 1 |
| Kimmig, JM | 1 |
| Fujimori, K | 1 |
| Suzuki, E | 1 |
| Arakawa, M | 1 |
| Richter, JE | 2 |
| Long, JF | 1 |
| Berges, W | 1 |
| Wienbeck, M | 1 |
| Inauen, W | 1 |
| Emde, C | 1 |
| Weber, B | 1 |
| Armstrong, D | 1 |
| Bettschen, HU | 1 |
| Huber, T | 1 |
| Scheurer, U | 1 |
| Halter, F | 1 |
| Merki, HS | 1 |
| Claussen, DW | 1 |
| Vandenplas, Y | 1 |
| Geldof, H | 2 |
| Hazelhoff, B | 1 |
| Otten, MH | 1 |
| Adami, B | 1 |
| Bouzo, MH | 2 |
| Brandstätter, G | 2 |
| Fumagalli, I | 1 |
| Galmiche, JP | 3 |
| Hebbeln, H | 1 |
| Hentschel, E | 3 |
| Hüttemann, W | 2 |
| SChütz, E | 1 |
| Robertson, CS | 1 |
| Evans, DF | 1 |
| Ledingham, SJ | 1 |
| Atkinson, M | 1 |
| Grey, MR | 1 |
| Yarze, JC | 1 |
| McKenna, CJ | 1 |
| Mills, JG | 1 |
| Goodwin, C | 1 |
| Wood, JR | 1 |
| McDougall, NI | 2 |
| Johnston, BT | 1 |
| Kee, F | 1 |
| Collins, JS | 2 |
| McFarland, RJ | 2 |
| Love, AH | 3 |
| Garrigues, V | 1 |
| Ponce, J | 1 |
| Gálvez, C | 1 |
| Valverde, J | 1 |
| Berenguer, J | 1 |
| Pollmann, H | 1 |
| Zillessen, E | 1 |
| Pohl, J | 1 |
| Rosemeyer, D | 1 |
| Abucar, A | 1 |
| Armbrecht, U | 1 |
| Bornhofen, B | 1 |
| Herz, R | 1 |
| Pouderoux, P | 1 |
| Kahrilas, PJ | 1 |
| Reynolds, JC | 1 |
| Haycox, A | 1 |
| Paterson, WG | 1 |
| Wang, H | 1 |
| Beck, IT | 1 |
| Snape, WJ | 1 |
| Corrado, G | 1 |
| D'Eufemia, P | 1 |
| Pacchiarotti, C | 1 |
| Cavaliere, M | 1 |
| Rea, P | 1 |
| Frandina, G | 1 |
| Giardini, O | 1 |
| Cardi, E | 1 |
| Katsoulis, S | 1 |
| Fölsch, UR | 1 |
| Watson, RG | 1 |
| Schütze, K | 2 |
| Bigard, MA | 1 |
| Van Waes, L | 1 |
| Hinojosa, J | 1 |
| Bedogni, G | 1 |
| Hatlebakk, JG | 1 |
| Johnsson, F | 1 |
| Vilien, M | 1 |
| Carling, L | 2 |
| Wetterhus, S | 1 |
| Thøgersen, T | 1 |
| Shibata, Y | 1 |
| Nimura, Y | 1 |
| Toyoda, S | 1 |
| Yasui, A | 1 |
| Kawamura, T | 1 |
| Chen, SD | 1 |
| Kao, CH | 1 |
| Chang, CS | 1 |
| Chen, GH | 1 |
| Holloway, RH | 1 |
| Penagini, R | 1 |
| Schoeman, MN | 1 |
| Dent, J | 1 |
| Anker Hansen, OJ | 1 |
| de Groot, GH | 1 |
| Glise, H | 1 |
| Efskind, P | 1 |
| Elsborg, L | 1 |
| Karvonen, AL | 1 |
| Ohlin, B | 1 |
| Koop, H | 1 |
| Toussaint, J | 1 |
| Gossuin, A | 1 |
| Deruyttere, M | 1 |
| Hublé, F | 1 |
| Devis, G | 1 |
| Nio, CY | 2 |
| Schotborgh, RH | 1 |
| Sekiguchi, T | 2 |
| Nishioka, T | 2 |
| Matsuzaki, T | 2 |
| Sugiyama, M | 1 |
| Kusano, M | 2 |
| Horikoshi, T | 2 |
| Toki, M | 1 |
| Ohwada, T | 1 |
| Kobayashi, S | 1 |
| Lepoutre, L | 1 |
| Van der Spek, P | 1 |
| Vanderlinden, I | 1 |
| Bollen, J | 1 |
| Laukens, P | 1 |
| Janisch, HD | 2 |
| Gelineck, J | 1 |
| Aksglade, K | 1 |
| Funch-Jensen, P | 1 |
| Thommesen, P | 1 |
| Maleev, A | 1 |
| Mendizova, A | 1 |
| Popov, P | 1 |
| Vlahov, V | 1 |
| Dimitrov, B | 1 |
| Mihova, A | 1 |
| Crowe, J | 1 |
| Silveira, J | 1 |
| Thomson, A | 1 |
| Routhier, G | 1 |
| Carrasco Gandía, S | 1 |
| Lama Moré, R | 1 |
| Prieto Bozano, G | 1 |
| Polanco Allue, I | 1 |
| Vantrappen, G | 1 |
| Janssens, J | 1 |
| Cloarec, D | 1 |
| Bruley des Varannes, S | 1 |
| Guslandi, M | 1 |
| Baldi, F | 1 |
| Bianchi Porro, G | 1 |
| Dobrilla, G | 1 |
| Iascone, C | 1 |
| Lobello, R | 1 |
| Marzio, L | 1 |
| Sabbatini, F | 1 |
| Tittobello, A | 1 |
| Verme, G | 1 |
| Evreux, M | 1 |
| Kerstan, E | 1 |
| Kratochvil, P | 1 |
| Reichel, W | 1 |
| Soule, JC | 1 |
| Vitaux, J | 1 |
| Cucchiara, S | 1 |
| Staiano, A | 1 |
| Capozzi, C | 1 |
| Di Lorenzo, C | 1 |
| Boccieri, A | 1 |
| Auricchio, S | 1 |
| Collins, BJ | 1 |
| Spence, RA | 1 |
| Ferguson, R | 1 |
| Laird, J | 1 |
| Machida, M | 1 |
| Kogure, M | 1 |
| Katoh, R | 1 |
| Fukagawa, H | 1 |
| Tajima, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404] | 98 participants (Actual) | Interventional | 2009-03-01 | Completed | |||
| Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study[NCT01574573] | 52 participants (Actual) | Interventional | 2009-06-30 | Terminated (stopped due to Closed due to lack of recruitment) | |||
| Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease: a Randomized Single-blind Study[NCT02706938] | 65 participants (Actual) | Interventional | 2016-04-08 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in Short Form 36 Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 100, with a higher punctuation meaning a better outcome. Quality of life change of ≥ 10 points from baseline was considered clinically relevant. (NCT02706938)
Timeframe: Secondary outcome will be assessed at baseline and 6 weeks after starting each period
| Intervention | scores on a scale (Mean) |
|---|---|
| Head of Bed Elevation | 6.5992 |
| Control | -0.3139 |
Change in Reflux Disease Questionnaire Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 6, with a higher punctuation meaning a worse outcome. Symptom change of ≥ 0,6 points from baseline was considered clinically relevant. (NCT02706938)
Timeframe: Primary outcome will be assessed at baseline and 6 weeks after starting each period
| Intervention | scores on a scale (Mean) |
|---|---|
| Head of Bed Elevation | -1.2397 |
| Control | 0.0869 |
Percentage of patients who preferred head of bed elevation after trial ending (NCT02706938)
Timeframe: Secondary outcome will be assessed 14 weeks after starting the trial
| Intervention | percent of participants (Number) |
|---|---|
| All Participants | 63.158 |
11 reviews available for cisapride and Esophagitis, Peptic
| Article | Year |
|---|---|
Gastrointestinal motility and prokinetics in the critically ill.
Topics: Cisapride; Critical Care; Enteral Nutrition; Erythromycin; Esophagitis, Peptic; Gastric Emptying; Ga | 2007 |
[Therapy of reflux esophagitis].
Topics: Anti-Ulcer Agents; Cisapride; Combined Modality Therapy; Esophagitis, Peptic; Female; Gastric Acidit | 1993 |
The diagnosis and treatment of gastro-oesophageal reflux disease in infants and children.
Topics: Anti-Ulcer Agents; Child, Preschool; Cisapride; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Ga | 1993 |
Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Cisapride; Drug Interactions; Drug Therapy, Combination; Esophagitis, Pepti | 1996 |
[Conservative therapy of reflux esophagitis].
Topics: Cisapride; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole; Piperidines; Serotonin | 1990 |
Reflux esophagitis.
Topics: Anti-Ulcer Agents; Cisapride; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole; Pip | 1990 |
Pathophysiology and treatment of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Esophagogastric Junctio | 1989 |
Drug therapy of reflux oesophagitis: an update.
Topics: Antacids; Bethanechol; Bethanechol Compounds; Cisapride; Domperidone; Esophagitis, Peptic; Histamine | 1989 |
Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review.
Topics: Adult; Child; Cisapride; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Me | 1989 |
[Reflux esophagitis: therapeutic indications].
Topics: Cisapride; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole; Piperidines | 1988 |
The medical therapy of reflux oesophagitis.
Topics: Antacids; Bethanechol; Bethanechol Compounds; Cimetidine; Cisapride; Domperidone; Esophagitis, Pepti | 1987 |
31 trials available for cisapride and Esophagitis, Peptic
| Article | Year |
|---|---|
A comparison of five maintenance therapies for reflux esophagitis.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Disease-Free Survival; Drug Therapy, Combination; Esophagitis, | 1995 |
Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease.
Topics: Cisapride; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Piperidines; Prognosis; Prospective | 1995 |
Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies.
Topics: Adult; Aged; Cisapride; Drug Administration Schedule; Drug Therapy, Combination; Esophagitis, Peptic | 1995 |
Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study.
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Drug Administration | 1995 |
Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.
Topics: Adult; Aged; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Drug Therapy, Combination; Esophagea | 1993 |
Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aluminum Hydroxide; Antacids; Cisapride; Double-Blind Me | 1993 |
Effect of cisapride on relapse of esophagitis. A multinational, placebo-controlled trial in patients healed with an antisecretory drug. The Italian Eurocis Trialists.
Topics: Cisapride; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Esophagoscopy; Fe | 1993 |
Cisapride in the treatment of gastro-oesophageal reflux disease.
Topics: Adult; Aged; Cisapride; Double-Blind Method; Endoscopy, Digestive System; Esophagitis, Peptic; Femal | 1993 |
Combination of ranitidine and cisapride in the treatment of reflux oesophagitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cisapride; Double-Blind Method; Dr | 1995 |
[Effect of elevated head position in bed in therapy of gastroesophageal reflux].
Topics: Adult; Antacids; Anti-Ulcer Agents; Cisapride; Combined Modality Therapy; Esophagitis, Peptic; Femal | 1996 |
A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Esophagitis, Peptic; Female; Gastric Acid; Gastric Acidity Dete | 1995 |
[Maintenance therapy in reflux esophagitis].
Topics: Adult; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Esophagitis, Peptic; Esophagoscopy; | 1997 |
Maintenance therapy with cisapride after healing of erosive oesophagitis: a double-blind placebo-controlled trial.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Hydro | 1997 |
Comparison of two dosing regimens of cisapride in the treatment of reflux oesophagitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Cisapride; Dosage Forms; Double-Blind Method; Esophagiti | 1997 |
The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.
Topics: Abdominal Pain; Cisapride; Constipation; Diarrhea; Drug Administration Schedule; Endoscopy; Esophagi | 1997 |
Salivary function in patients with reflux esophagitis: effect of cisapride.
Topics: Cisapride; Esophagitis, Peptic; Fasting; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; | 1998 |
Effect of cisapride on secondary peristalsis in patients with gastroesophageal reflux disease.
Topics: Adult; Aged; Cisapride; Cross-Over Studies; Double-Blind Method; Esophagitis, Peptic; Esophagus; Fem | 1999 |
Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug.
Topics: Anti-Ulcer Agents; Cisapride; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; Middle | 1992 |
Healing and prevention of relapse of reflux oesophagitis by cisapride.
Topics: Adolescent; Adult; Aged; Cisapride; Double-Blind Method; Esophagitis, Peptic; Esophagus; Female; Hum | 1991 |
Healing of grade-II and III oesophagitis through motility stimulation with cisapride.
Topics: Adult; Cisapride; Double-Blind Method; Esophagitis, Peptic; Esophagus; Humans; Peristalsis; Piperidi | 1990 |
[A chance for conservative treatment of reflux disease. Can it be used preventively in malignant changes?].
Topics: Adolescent; Adult; Aged; Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophageal Neopla | 1990 |
[Cisapride versus ranitidine in reflux esophagitis].
Topics: Adult; Antacids; Cisapride; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; Piperidi | 1990 |
Influence of cisapride on food-stimulated gastro-oesophageal reflux: a radiological study.
Topics: Adult; Aged; Barium Sulfate; Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophagitis, | 1990 |
Cisapride and cimetidine in the treatment of erosive esophagitis.
Topics: Cimetidine; Cisapride; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Femal | 1990 |
Pathophysiology and treatment of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Esophagogastric Junctio | 1989 |
Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review.
Topics: Adult; Child; Cisapride; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Me | 1989 |
Cisapride versus ranitidine in the treatment of reflux esophagitis.
Topics: Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; | 1988 |
Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial.
Topics: Adult; Cisapride; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Female; Humans; Male; Mid | 1988 |
Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial.
Topics: Adult; Aged; Cimetidine; Cisapride; Clinical Trials as Topic; Double-Blind Method; Drug Combinations | 1988 |
Cisapride for gastro-oesophageal reflux and peptic oesophagitis.
Topics: Child, Preschool; Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Fem | 1987 |
Cisapride: influence on oesophageal and gastric emptying and gastro-oesophageal reflux in patients with reflux oesophagitis.
Topics: Adult; Aged; Cisapride; Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Female; | 1987 |
17 other studies available for cisapride and Esophagitis, Peptic
| Article | Year |
|---|---|
Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Biomarkers; Cisapride; Disease Models | 2011 |
[A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride].
Topics: Asthma; Cisapride; Esophagitis, Peptic; Humans; Male; Middle Aged; Omeprazole; Peak Expiratory Flow | 1994 |
Propulsid (cisapride).
Topics: Cisapride; Drug Interactions; Esophagitis, Peptic; Humans; Piperidines | 1994 |
Cisapride for nocturnal heartburn.
Topics: Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Gastroesophageal Reflux; Heartburn; Humans | 1994 |
Maintenance therapies for reflux esophagitis.
Topics: Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Esophagitis, Peptic; Humans; Omeprazole; Pa | 1996 |
Maintenance therapies for reflux esophagitis.
Topics: Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Esophagitis, Peptic; Humans; Omeprazole; Pi | 1996 |
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Barrett Esophagus; Cisapride; Deglutition Disorders; Disea | 1996 |
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Barrett Esophagus; Cisapride; Deglutition Disorders; Disea | 1996 |
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Barrett Esophagus; Cisapride; Deglutition Disorders; Disea | 1996 |
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Barrett Esophagus; Cisapride; Deglutition Disorders; Disea | 1996 |
Achalasia-like syndrome as the first manifestation in a patient with CREST syndrome.
Topics: Anti-Ulcer Agents; Cardia; Cisapride; Constipation; CREST Syndrome; Dilatation; Esophageal Achalasia | 1996 |
[Management of dyspepsia. Management plan aimed at prevention of upper abdominal complaints].
Topics: Abdominal Pain; Anti-Ulcer Agents; Cisapride; Dyspepsia; Esophagitis, Peptic; Humans; Piperidines | 1996 |
The effect of cisapride in patients with reflux esophagitis: an ambulatory esophageal manometry/pH-metry study.
Topics: Adult; Aged; Ambulatory Care; Anti-Ulcer Agents; Cisapride; Drug Evaluation; Esophagitis, Peptic; Es | 1997 |
Managing the patient with atypical chest pain.
Topics: Adrenergic Uptake Inhibitors; Algorithms; Amitriptyline; Anti-Ulcer Agents; Atropine; Chest Pain; Ci | 1997 |
Irritable oesophagus syndrome as cause of chronic cough.
Topics: Chronic Disease; Cisapride; Cough; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Hydrogen-Io | 1996 |
Acid reflux test for gastroesophageal reflux after distal gastrectomy: diagnosis and clinical effect of cisapride.
Topics: Adult; Aged; Anti-Ulcer Agents; Barium Sulfate; Chest Pain; Cisapride; Contrast Media; Esophagitis, | 1998 |
Comparative efficacy of acid reflux inhibition by drug therapy in reflux esophagitis.
Topics: Adult; Aged; Chronic Disease; Cisapride; Esophagitis, Peptic; Esophagus; Famotidine; Female; Humans; | 1991 |
[Results of the treatment of gastroesophageal reflux and peptic esophagitis using cisapride].
Topics: Cisapride; Esophagitis, Peptic; Female; Gastric Emptying; Gastric Juice; Gastroesophageal Reflux; Hu | 1990 |
Cimetidine plus cisapride for reflux oesophagitis.
Topics: Cimetidine; Cisapride; Drug Therapy, Combination; Esophagitis, Peptic; Humans; Piperidines | 1988 |
[Effects of cisapride on lower esophageal sphincter pressure and gastroduodenal motor activity in man].
Topics: Adolescent; Adult; Aged; Cisapride; Duodenum; Electromyography; Esophagitis, Peptic; Esophagogastric | 1986 |